» Articles » PMID: 9623978

Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain from an Inhibitor to a Potent Activator of FGF-2

Overview
Journal Nat Med
Date 1998 Jun 12
PMID 9623978
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

The activity of fibroblast growth factor 2 (FGF-2) is stringently controlled. Inactive in undisturbed tissues, it is activated during injury and is critical for tissue repair. We find that this control can be imposed by the soluble syndecan-1 ectodomain, a heparan sulfate proteoglycan shed from cell surfaces into wound fluids. The ectodomain potently inhibits heparin-mediated FGF-2 mitogenicity because of the poorly sulfated domains in its heparin sulfate chains. Degradation of these regions by platelet heparanase produces heparin-like heparin sulfate fragments that markedly activate FGF-2 mitogenicity and are found in wound fluids. These results establish a novel physiological control for FGF-2 and suggest new ways to modulate FGF activity.

Citing Articles

Neuronal Wiring Receptors Dprs and DIPs Are GPI Anchored and This Modification Contributes to Their Cell Surface Organization.

Lobb-Rabe M, Nawrocka W, Zhang R, Ashley J, Carrillo R, Ozkan E eNeuro. 2024; 11(2).

PMID: 38233143 PMC: 10863630. DOI: 10.1523/ENEURO.0184-23.2023.


Role of Syndecan-4 in the Inhibition of Articular Cartilage Degeneration in Osteoarthritis.

Hattori Y, Hasegawa M, Iino T, Imanaka-Yoshida K, Sudo A Biomedicines. 2023; 11(8).

PMID: 37626753 PMC: 10452293. DOI: 10.3390/biomedicines11082257.


Role of heparanase in ARDS through autophagy and exosome pathway (review).

Feng F, Wang L, Li J, Chen T, Liu L Front Pharmacol. 2023; 14:1200782.

PMID: 37361227 PMC: 10285077. DOI: 10.3389/fphar.2023.1200782.


Heparanase regulates EMT and cancer stem cell properties in prostate tumors.

Masola V, Franchi M, Zaza G, Atsina F, Gambaro G, Onisto M Front Oncol. 2022; 12:918419.

PMID: 35965510 PMC: 9363836. DOI: 10.3389/fonc.2022.918419.


Targeting syndecan-1: new opportunities in cancer therapy.

Yang Z, Chen S, Ying H, Yao W Am J Physiol Cell Physiol. 2022; 323(1):C29-C45.

PMID: 35584326 PMC: 9236862. DOI: 10.1152/ajpcell.00024.2022.